TENAX THERAPEUTICS, INC. Comprehensive Income
TENAX THERAPEUTICS, INC. (TENX) reported Comprehensive Income of $7.71 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-28.
Discontinued › Income Statement
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2024-03-28
- TENAX THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2022-12-31 was $2.55M.
- TENAX THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2022-09-30 was $2.92M, a 23.22% decline year-over-year.
- TENAX THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2022-06-30 was $2.86M, a 66.64% increase year-over-year.
- TENAX THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2022-03-31 was $2.72M, a 88.54% decline year-over-year.
- TENAX THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was $7.71M, a 30.21% decline from fiscal 2022.
- TENAX THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was $11.05M.
- TENAX THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2021 was -$32.47M, a 429.62% decline from fiscal 2020.
- TENAX THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2020 was $9.85M, a 17.36% increase from fiscal 2019.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 8 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | $7.71M 10-K · filed 2024-03-28 | ||||||||
| 2022-12-31 | $2.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $5.47M derived: sum of 2 quarters · filed 2024-03-28 | $8.33M derived: sum of 3 quarters · filed 2024-03-28 | $11.05M 10-K · filed 2024-03-28 | -$11.05M 10-K · filed 2023-03-31 | ||||
| 2022-09-30 | $2.92M 10-Q · filed 2022-11-10 | $5.78M derived: sum of 2 quarters · filed 2022-11-10 | $8.50M 10-Q · filed 2022-11-10 | -$53.24M derived: sum of 4 quarters · filed 2023-03-31 | |||||
| 2022-06-30 | $2.86M 10-Q · filed 2022-08-11 | $5.58M 10-Q · filed 2022-08-11 | -$56.16M derived: sum of 3 quarters · filed 2023-03-31 | -$52.36M derived: sum of 4 quarters · filed 2023-03-31 | |||||
| 2022-03-31 | $2.72M 10-Q · filed 2022-05-16 | -$59.02M derived: sum of 2 quarters · filed 2023-03-31 | -$55.22M derived: sum of 3 quarters · filed 2023-03-31 | -$53.50M derived: sum of 4 quarters · filed 2023-03-31 | |||||
| 2021-12-31 | -$61.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$57.94M derived: sum of 2 quarters · filed 2023-03-31 | -$56.22M derived: sum of 3 quarters · filed 2023-03-31 | -$32.47M 10-K · filed 2023-03-31 | $32.47M 10-K · filed 2022-03-29 | ||||
| 2021-09-30 | $3.80M 10-Q · filed 2022-11-10 | $5.52M derived: sum of 2 quarters · filed 2022-11-10 | $29.26M 10-Q · filed 2022-11-10 | $32.09M derived: sum of 4 quarters · filed 2022-11-10 | |||||
| 2021-06-30 | $1.72M 10-Q · filed 2022-08-11 | $25.47M 10-Q · filed 2022-08-11 | $28.30M derived: sum of 3 quarters · filed 2022-08-11 | $30.52M derived: sum of 4 quarters · filed 2022-08-11 | |||||
| 2021-03-31 | $23.75M 10-Q · filed 2022-05-16 | $26.58M derived: sum of 2 quarters · filed 2022-05-16 | $28.80M derived: sum of 3 quarters · filed 2022-05-16 | $30.94M derived: sum of 4 quarters · filed 2022-05-16 | |||||
| 2020-12-31 | $2.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $5.05M derived: sum of 2 quarters · filed 2022-03-29 | $7.20M derived: sum of 3 quarters · filed 2022-03-29 | $9.85M 10-K · filed 2022-03-29 | |||||
| 2020-09-30 | $2.22M 10-Q · filed 2021-11-15 | $4.36M derived: sum of 2 quarters · filed 2021-11-15 | $7.02M 10-Q · filed 2021-11-15 | $9.81M derived: sum of 4 quarters · filed 2021-11-15 | |||||
| 2020-06-30 | $2.14M 10-Q · filed 2021-08-16 | $4.80M 10-Q · filed 2021-08-16 | $7.59M derived: sum of 3 quarters · filed 2021-08-16 | $9.82M derived: sum of 4 quarters · filed 2021-08-16 | |||||
| 2020-03-31 | $2.66M 10-Q · filed 2021-05-17 | $5.45M derived: sum of 2 quarters · filed 2021-05-17 | $7.67M derived: sum of 3 quarters · filed 2021-05-17 | $9.43M derived: sum of 4 quarters · filed 2021-05-17 | |||||
| 2019-12-31 | $2.79M derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-04-16 | $5.02M derived: sum of 2 quarters · filed 2021-04-16 | $6.78M derived: sum of 3 quarters · filed 2021-04-16 | $8.39M 10-K/A · filed 2021-04-16 | |||||
| 2019-09-30 | $2.22M 10-Q · filed 2020-11-16 | $3.99M derived: sum of 2 quarters · filed 2020-11-16 | $5.60M 10-Q · filed 2020-11-16 | $15.14M derived: sum of 4 quarters · filed 2020-11-16 | |||||
| 2019-06-30 | $1.76M 10-Q · filed 2020-08-14 | $3.38M 10-Q · filed 2020-08-14 | $12.91M derived: sum of 3 quarters · filed 2020-08-14 | $14.44M derived: sum of 4 quarters · filed 2020-08-14 | |||||
| 2019-03-31 | $1.62M 10-Q · filed 2020-05-15 | $11.15M derived: sum of 2 quarters · filed 2020-05-15 | $12.68M derived: sum of 3 quarters · filed 2020-05-15 | $14.54M derived: sum of 4 quarters · filed 2020-05-15 | |||||
| 2018-12-31 | $9.54M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $11.07M derived: sum of 2 quarters · filed 2020-03-30 | $12.92M derived: sum of 3 quarters · filed 2020-03-30 | $14.13M 10-K · filed 2020-03-30 | |||||
| 2018-09-30 | $1.53M 10-Q · filed 2019-11-14 | $1.52M 10-Q · filed 2018-11-14 | $3.39M derived: sum of 2 quarters · filed 2019-11-14 | $4.59M 10-Q · filed 2019-11-14 | $4.58M 10-Q · filed 2018-11-14 | $5.94M derived: sum of 4 quarters · filed 2019-11-14 | |||
| 2018-06-30 | $1.86M 10-Q · filed 2019-08-14 | $1.86M 10-Q · filed 2018-08-14 | $3.06M 10-Q · filed 2019-08-14 | $3.05M 10-Q · filed 2018-08-14 | $4.42M derived: sum of 3 quarters · filed 2019-08-14 | $5.65M derived: sum of 4 quarters · filed 2019-08-14 | |||
| 2018-03-31 | $1.20M 10-Q · filed 2019-05-15 | $1.19M 10-Q · filed 2018-05-15 | $2.56M derived: sum of 2 quarters · filed 2019-05-15 | $3.79M derived: sum of 3 quarters · filed 2019-05-15 | $6.77M derived: sum of 4 quarters · filed 2019-05-15 | ||||
| 2017-12-31 | $1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $2.58M derived: sum of 2 quarters · filed 2019-04-01 | $5.57M derived: sum of 3 quarters · filed 2019-04-01 | $8.84M 10-K · filed 2019-04-01 | |||||
| 2017-09-30 | $1.23M 10-Q · filed 2018-11-14 | $4.21M derived: sum of 2 quarters · filed 2018-11-14 | $7.48M 10-Q · filed 2018-11-14 | $37.20M derived: sum of 4 quarters · filed 2018-11-14 | |||||
| 2017-06-30 | $2.98M 10-Q · filed 2018-08-14 | $6.25M 10-Q · filed 2018-08-14 | $35.97M derived: sum of 3 quarters · filed 2018-08-14 | $40.28M derived: sum of 4 quarters · filed 2018-08-14 | |||||
| 2017-03-31 | $3.27M 10-Q · filed 2018-05-15 | $32.98M derived: sum of 2 quarters · filed 2018-05-15 | $37.30M derived: sum of 3 quarters · filed 2018-05-15 | $41.86M derived: sum of 4 quarters · filed 2018-05-15 | |||||
| 2016-12-31 | $29.72M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $34.03M derived: sum of 2 quarters · filed 2018-04-02 | $38.59M derived: sum of 3 quarters · filed 2018-04-02 | $43.81M 10-K · filed 2018-04-02 | |||||
| 2016-09-30 | $4.31M 10-Q · filed 2017-11-09 | $8.88M derived: sum of 2 quarters · filed 2017-11-09 | $14.10M 10-Q · filed 2017-11-09 | ||||||
| 2016-06-30 | $4.56M 10-Q · filed 2017-08-09 | $9.78M 10-Q · filed 2017-08-09 | |||||||
| 2016-03-31 | $5.22M 10-Q · filed 2017-05-10 | ||||||||
| 2015-12-31 | $10.22M 10-K · filed 2017-03-16 | ||||||||
| 2015-10-31 | $3.50M 10-Q · filed 2015-12-10 | $6.60M 10-Q · filed 2015-12-10 | |||||||
| 2015-09-30 | $2.91M 10-Q · filed 2016-11-09 | $10.49M 10-Q · filed 2016-11-09 | |||||||
| 2015-07-31 | $3.10M 10-Q · filed 2015-09-09 | ||||||||
| 2015-06-30 | $4.82M 10-Q · filed 2016-08-09 | $7.58M 10-Q · filed 2016-08-09 | |||||||
| 2015-04-30 | $5.01M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $14.06M 10-K · filed 2017-03-16 | |||||||
| 2015-03-31 | $2.76M 10-Q · filed 2016-05-10 | ||||||||
| 2015-01-31 | $2.77M 10-Q · filed 2015-03-17 | $6.80M derived: sum of 2 quarters · filed 2015-12-10 | $9.04M 10-Q · filed 2015-03-17 | $19.46M derived: sum of 4 quarters · filed 2017-03-16 | |||||
| 2014-10-31 | $4.03M 10-Q · filed 2015-12-10 | $6.27M 10-Q · filed 2015-12-10 | $16.68M derived: sum of 3 quarters · filed 2017-03-16 | $20.03M derived: sum of 4 quarters · filed 2017-03-16 | |||||
| 2014-07-31 | $2.24M 10-Q · filed 2015-09-09 | $12.65M derived: sum of 2 quarters · filed 2017-03-16 | $16.00M derived: sum of 3 quarters · filed 2017-03-16 | $19.53M derived: sum of 4 quarters · filed 2017-03-16 | |||||
| 2014-04-30 | $10.41M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $13.77M derived: sum of 2 quarters · filed 2017-03-16 | $17.30M derived: sum of 3 quarters · filed 2017-03-16 | $19.54M 10-K · filed 2017-03-16 | |||||
| 2014-01-31 | $3.35M 10-Q · filed 2015-03-17 | $6.88M derived: sum of 2 quarters · filed 2015-03-17 | $9.13M 10-Q · filed 2015-03-17 | ||||||
| 2013-10-31 | $3.53M 10-Q · filed 2014-12-15 | $5.78M 10-Q · filed 2014-12-15 | |||||||
| 2013-07-31 | $4.34M 10-Q · filed 2014-09-15 | ||||||||
| 2013-04-30 | $9.42M 10-KT · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |